Overview
- A urine sample taken at the ATP 250 in Mallorca on June 22 tested positive for benzoilecgonine and a WADA‑accredited laboratory confirmed the result on July 17.
- The International Tennis Integrity Agency provisionally suspended Kyrgios on August 4 and, after an interview and independent expert review, accepted his account that the consumption occurred out of competition.
- Under WADA rules the default out‑of‑competition sanction is three months but the ITIA offered a reduction to one month if he entered an approved treatment program, which Kyrgios accepted and began.
- The one‑month suspension concluded on Thursday, September 3, the ITIA withdrew his €6,570 prize money and the ranking points from Mallorca, and his eligibility to compete has been restored subject to program completion.
- Kyrgios has apologised, linked the episode to injury and personal struggles, has not named a return event and will play only after the US Open — the case highlights how anti‑doping rules treat recreational stimulant use outside competition and may affect his ranking and season momentum.